CUV 1.61% $14.68 clinuvel pharmaceuticals limited

Ann: Appendix 4E and Annual Report 2022, page-10

  1. 1,969 Posts.
    lightbulb Created with Sketch. 158
    NPAT is just accounting opinion and easily manipulated
    As evident by Clinuvel results
    The market does not care NPAT fell this year because of above

    EBIT much better
    Cash flow even better
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.